Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 4/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | PRKCI | P41743 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853505 | 0.91 | CA9 (0.44) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL26775387 | 0.91 | CA9 (0.44) | CA12CA9GRM5GSK3BNTRK1 | |
| M-Xylene SCHEMBL1784159 | 0.87 | CLK4 (0.55) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL29584703 | 0.84 | NTRK2 (0.56) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL4499446 | 0.84 | NTRK2 (0.56) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL26775545 | 0.81 | KDR (0.39) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL1417646 | 0.81 | PARP10 (0.64) | GRM5MAOAMAOBPRKCIPARP1 | |
| SCHEMBL9477764 | 0.80 | NTRK1 (0.59) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL26775543 | 0.79 | CLK4 (0.46) | CA12CA9GRM5GSK3BNTRK1 | |
| SCHEMBL22451521 | 0.78 | ESR1 (0.47) | CA12CA9MAOAMAOBPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024263563-A1 | METABOTROPIC GLUTAMATE SUBTYPE-2 AND -3 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| CN-113474340-B | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-114763357-B | Indolopyrimidine tricyclic compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-06-18 | — | — | CN | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5821256-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-10-13 | — | — | US | disclosed |
| CN-1149583-A | Enderma agent receptor antagonist | MERCK PATENT GMBH (DE) | 1997-05-14 | — | — | CN | disclosed |
| EP-0758650-A1 | Endothelin receptor antagonists | MERCK PATENT GmbH (DE) | 1997-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | CA12 4590/4885CA9 4407/4885GRM5 1315/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CA12 4822/4885CA9 4490/4885GRM5 4803/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | CA12 4780/4885CA9 3181/4885GRM5 4794/4885 |
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | NRAS, KRAS, RASSF5 | CA12 4718/4885CA9 4325/4885GRM5 3473/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | CA12 922/4885CA9 304/4885GRM5 4657/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | CA12 4831/4885CA9 4638/4885GRM5 4732/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | CA12 4794/4885CA9 4489/4885GRM5 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.